{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:04:17Z","timestamp":1777395857541,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2021,9,28]]},"abstract":"<jats:p>Background: For care planning and support, under-detection and late diagnosis of Alzheimer\u2019s disease (AD) is a great challenge. Models of Patient-Engagement for Alzheimer\u2019s Disease (MOPEAD) is an EU-funded project aiming at testing different strategies to improve this situation. Objective: To make a cost-consequence analysis of MOPEAD. Methods: Four screening strategies were tested in five countries (Germany, the Netherlands, Slovenia, Spain, and Sweden): 1) a web-approach; 2) Open-House initiative; 3) in primary care; and 4) by diabetes specialists. Persons-at-risk of AD in all strategies were offered referral to a hospital-based specialist. The primary health-economic outcome was the cost per true-positive case (TP) of AD from the screened population. Results: Of 2,847 screened persons, 1,121 screened positive (39%), 402 were evaluated at memory clinics (14%), and 236 got an AD diagnosis (8%). The cost per TP of those screened was \u20ac3,115 with the web-approach, \u20ac2,722 with the Open-House, \u20ac1,530 in primary care, and \u20ac1,190 by diabetes specialists. Sensitivity analyses that more likely reflect the real-world situation confirmed the results. The number-needed-to-screen was 30 with the web-approach, 8 with the Open-House and primary care, and 6 with the diabetes specialists. There were country differences in terms of screening rates, referrals to memory clinics, staff-types involved, and costs per TP. Conclusion: In primary care and by the diabetes specialist, the costs per TP\/screened population were lowest, but the capacity of such settings to identify cases with AD-risk must be discussed. Hence new diagnostic strategies such as web-solutions and Open-House initiatives may be valuable after modifications.<\/jats:p>","DOI":"10.3233\/jad-210303","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T14:07:45Z","timestamp":1629209265000},"page":"1149-1159","source":"Crossref","is-referenced-by-count":7,"title":["A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer\u2019s Disease: Results from the MOPEAD Project"],"prefix":"10.1177","volume":"83","author":[{"given":"Anders","family":"Wimo","sequence":"first","affiliation":[{"name":"Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Collaborators and members of the MOPEAD consortium EscherClausDepartment of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany (Claus.Escher@ukbonn.de) M\u00fcllerTheresaDepartment of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany (theresa.mueller@uk-koeln.de) BogdanovicNenadKarolinska University Hospital, Theme Inflammation and Aging, Huddinge, Sweden (nenad.bogdanovic@sll.se) AndersenPiaKarolinska University Hospital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Belger","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Ltd (ELI), Bracknell, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaka","family":"Bon","sequence":"additional","affiliation":[{"name":"University Medical Centre Ljubljana (UMCL), Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry, Cologne, Germany"},{"name":"Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) Universit\u00e4t zu K\u00f6ln, K\u00f6ln, Germany"},{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen (DZNE), Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Dumas","sequence":"additional","affiliation":[{"name":"ASDM Consulting, EU Affairs Director, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milica G.","family":"Kramberger","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Center Ljubljana and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Jamilis","sequence":"additional","affiliation":[{"name":"GMV Soluciones Globales Internet S.A.U. (GMV), Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunilla","family":"Johansson","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Care sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"Rodrigo Salas","sequence":"additional","affiliation":[{"name":"GMV Soluciones Globales Internet S.A.U. (GMV), Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Octavio","family":"Rodr\u00edguez G\u00f3mez","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 ACE (FACE), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Sannemann","sequence":"additional","affiliation":[{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malou","family":"Stoekenbroek","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, VU University, Amsterdam, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miren","family":"Gurruchaga Telleria","sequence":"additional","affiliation":[{"name":"Research Center and Memory Clinic, Fundaci\u00f3 ACE, Institut Catal\u00e0 de Neuroci\u00e8ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergi","family":"Valero","sequence":"additional","affiliation":[{"name":"Research Center and Memory Clinic, Fundaci\u00f3 ACE, Institut Catal\u00e0 de Neuroci\u00e8ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain"},{"name":"Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Vermunt","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, VU University, Amsterdam, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Waterink","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, VU University, Amsterdam, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden"},{"name":"Karolinska University Hospital, Theme Inflammation and Aging, Huddinge, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Jelle","family":"Visser","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, VU University, Amsterdam, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Zwan","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, VU University, Amsterdam, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 ACE (FACE), Barcelona, Spain"},{"name":"Research Center and Memory Clinic, Fundaci\u00f3 ACE, Institut Catal\u00e0 de Neuroci\u00e8ncies Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain"},{"name":"Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-210303_ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2016.07.150","article-title":"The worldwide costs of dementia 2015 and comparisons with 2010","volume":"13","author":"Wimo","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-210303_ref4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer\u2019s disease and other dementias: A priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-210303_ref5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1368-504X.2005.00480.x","article-title":"Inequalities in dementia care across Europe: Key findings of the Facing Dementia Survey","volume":"59","author":"Bond","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.3233\/JAD-210303_ref7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3233\/JAD-140354","article-title":"Rates of formal diagnosis in people screened positive for dementia in primary care: Results of the DelpHi-Trial","volume":"42","author":"Eichler","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-210303_ref8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.dadm.2014.11.007","article-title":"Rates of formal diagnosis of dementia in primary care: The effect of screening","volume":"1","author":"Eichler","year":"2015","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-210303_ref9","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jalz.2019.02.003","article-title":"The MOPEAD project: Advancing patient engagement for the detection of \u201chidden\u201d undiagnosed cases of Alzheimer\u2019s disease in the community","volume":"15","author":"Rodriguez-Gomez","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-210303_ref10","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/S0140-6736(18)32205-0","article-title":"Implementation research: New imperatives and opportunities in global health","volume":"392","author":"Theobald","year":"2018","journal-title":"Lancet"},{"key":"10.3233\/JAD-210303_ref11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00019053-199813030-00002","article-title":"The role of cost-consequence analysis in healthcare decision-making","volume":"13","author":"Mauskopf","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"10.3233\/JAD-210303_ref12","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.3233\/JAD-179905","article-title":"The end of the beginning of the Alzheimer\u2019s disease nightmare: A devil\u2019s advocate\u2019s view","volume":"64","author":"Wimo","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-210303_ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737167.2021.1848551","article-title":"What are the difficulties of implementing innovative pharmacy practice models in the care of patients with dementia?","volume":"21","author":"Wimo","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.3233\/JAD-210303_ref16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00259-011-2045-0","article-title":"Abeta Imaging: Feasible, pertinent, and vital to progress in Alzheimer\u2019s disease","volume":"39","author":"Villemagne","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-210303_ref17","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med"},{"key":"10.3233\/JAD-210303_ref18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00259-011-1960-4","article-title":"Amyloid-beta imaging with PET in Alzheimer\u2019s disease: Is it feasible with current radiotracers and technologies?","volume":"39","author":"Moghbel","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-210303_ref19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3233\/JAD-130485","article-title":"Amyloid-beta positron emission tomography imaging probes: A critical review","volume":"36","author":"Kepe","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-210303_ref20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3233\/JAD-180050","article-title":"Circular inference in dementia diagnostics","volume":"63","author":"Hoilund-Carlsen","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-210303_ref21","doi-asserted-by":"crossref","first-page":"e12130","DOI":"10.1002\/dad2.12130","article-title":"General practitioners\u2019 attitude toward early and pre-dementia diagnosis of AD in five European countries-A MOPEAD project survey","volume":"13","author":"Sannemann","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-210303_ref22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1474-4422(06)70537-3","article-title":"Risk score for the prediction of dementia risk in 20 years among middle aged people: A longitudinal, population-based study","volume":"5","author":"Kivipelto","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-210303_ref23","first-page":"903645","article-title":"The impact of experience with a family member with Alzheimer\u2019s disease on views about the disease across five countries","volume":"2012","author":"Blendon","year":"2012","journal-title":"Int J Alzheimers Dis"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-210303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:06:56Z","timestamp":1777370816000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-210303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":18,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-210303","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}